ASCO: AstraZeneca Changes Management Of Breast Cancer Resistance With SERENA-6
Study Supports Early Switching To Camizestrant Based On ctDNA Testing
AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.
